Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
2024-02-19 17:55:04 ET Almirall, S.A. (LBTSF) Q4 2023 Earnings Conference Call February 19, 2024, 04:00 AM ET Company Participants Pablo Divasson - Director, IR and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - CFO Karl Ziegelba...
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...
Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...
The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223 ALM223 has the potential to rebalance the immune system in several autoimmune diseases 1,2 Almirall S.A. (BME: ALM ) , a global pharmaceutical compa...
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront a...
Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signalling 1-4 Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demons...
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases Almirall S.A. (BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, and Absci Corpo...
2023-11-11 00:59:06 ET Almirall, S.A. (LBTSF) Q3 2023 Earnings Conference Call November 9, 2023, 4:00 AM ET Company Participants Pablo Divasson - Director, Investor Relations and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - Chief F...
Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performance Almirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the su...
First readout of two-year data from long-term extension study 43rd Annual Fall Clinical Dermatology Conference Almirall S.A. (BME:ALM ), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension study ...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Strong growth trajectory maintained with Net Sales increase of 6.7% to a total of €497.2 MM, EBITDA of €104.5 MM (+3.2% YoY) driven by increased overall sales and strong performance of biologics portfolio Biologics continue to be key growth engines for Almirall: Ebglyss ...
Lebrikizumab is recommended by NICE for the use in moderate to severe Atopic Dermatitis in patients 12 years and over when their condition has not responded to at least 1 systemic immunosuppressant, or when these treatments are not suitable Following approval of the European Commission (Octob...
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...